Back
Full-text
Journal article

Should We Consider the Cardiovascular System While Evaluating CKD-MBD?

  • Rroji M University Department of Nephrology, Faculty of Medicine, University of Medicine Tirana, Tirana 1001, Albania.
  • Figurek A Institute of Anatomy, University of Zurich, 8057 Zurich, Switzerland.
  • Spasovski G University Department of Nephrology, Medical Faculty, University of Skopje, Skopje 1000, North Macedonia.
  • 2020-02-29
Published in:
  • Toxins. - 2020
FGF23
PTH
chronic kidney disease
klotho
left ventricular hypertrophy
phosphate
sclerostin.
uremic cardiopathy
English Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis. The presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) has shown a strong correlation with CV events and mortality. As a non-atheromatous process, it could be partially explained why standard CV disease-modifying drugs do not provide such an impact on CV mortality in CKD as observed in the general population. We summarize the potential association of CV comorbidities with the older (parathyroid hormone, phosphate) and newer (FGF23, Klotho, sclerostin) CKD-MBD biomarkers.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/297202
Statistics
Document views: 36 File downloads:
  • Full-text: 0